TAMPA, Fla., May 2, 2011 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID") (Nasdaq:PSID), a leader in next-generation patient monitoring and diagnostics, and VGo Communications, Inc. ("VGo"), the leading provider of robotic telepresence solutions, announced today that the companies will host a joint demonstration of their innovative wireless health solutions working together at the American Telemedicine Association Annual International Meeting and Exhibition 2011 in Tampa, Florida. The companies will demonstrate PositiveID's iglucose™ wireless communication device for diabetes management operating in conjunction with VGo's robotic telepresence to show the ability of wireless technology to transform healthcare through mobile interaction between patients and healthcare providers.
Demonstration Details
Demos will take place twice daily on May 2 and 3 at 12:30 pm ET and 2:30 pm ET in PositiveID's booth (#1340).
The live demonstration will show a student using iglucose in a hypothetical classroom environment. Once the student checks her blood glucose readings, a text message will be sent via iglucose to the "remote school nurse" (in Boston). The student's low blood sugar reading will prompt the nurse, using a VGo, to check on the student in Tampa. The VGo will travel from its booth (#1040) to booth #1340, all under the control of the nurse in Boston. The nurse will then have a short face-to-face conversation with the student and advise the student of actions to take to stabilize her blood sugar.
About iglucose
iglucose uses the power of mobile technology to revolutionize the way individuals with diabetes manage their condition. iglucose wirelessly communicates blood glucose readings from data-capable glucometers to the iglucose database, where they can be shared with family members and health care professionals via email, text message or the database itself. For the 25.8 million Americans with diabetes, iglucose can help revolutionize the way they manage their disease, while reducing costs and providing greater convenience and freedom.
About VGo
Through VGo's robotic telepresence, an individual's presence is established in a distant location such that they can interact and perform their job in ways not previously possible. VGo allows an individual to see, hear, interact and move around in any remote site, just as if that person were there. VGo is not a videoconferencing/telepresence solution. With a videoconference, two or more people meet through TV monitors or PCs where people on both sides of the call must be sitting there in front the camera. With VGo, a person is completely independent of the people in the remote location. VGo's remote controlled mobility and physical presence makes it something totally new.
About VGo Communications, Inc.
VGo Communications, Inc. develops and markets visual communications solutions for the workplace. VGo's experienced successful veterans of visual communications and robotics industries are leveraging the recent trends of widespread wireless high speed networks, lower specialized component costs and the universal acceptance of video as a communications medium to create a new market category called "Robotic Telepresence."
About PositiveID Corporation
PositiveID Corporation develops and markets healthcare and information management products through its diagnostic devices and identification technologies, and its proprietary disease management tools. PositiveID's implantable healthcare devices and external hardware and software products are designed to communicate wirelessly to improve healthcare and the patient's quality of life. For more information on PositiveID, please visit .
The PositiveID Corporation logo is available at
Statements about PositiveID's future expectations, including the ability of iglucose to transform healthcare through mobile interaction between patients and healthcare providers; the ability of iglucose to use the power of mobile technology to revolutionize the way individuals with diabetes manage their condition; the likelihood that iglucose can help revolutionize the way the 25.8 million Americans with diabetes manage their disease while reducing costs and providing greater convenience and freedom; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include the Company's ability to successfully commercialize iglucose, as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT: Allison Tomek 561-805-8000 atomek@positiveidcorp.com Dan Schustack CEOcast 212-732-4300 dschustack@ceocast.com
